Search

Your search keyword '"Schuchter, Lynn"' showing total 982 results
Start Over Author "Schuchter, Lynn"
982 results on '"Schuchter, Lynn"'

1. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells

Author

Wang, Kevin, Coutifaris, Paulina, Brocks, David, Wang, Guanning, Azar, Tarek, Solis, Sabrina, Nandi, Ajeya, Anderson, Shaneaka, Han, Nicholas, Manne, Sasikanth, Kiner, Evgeny, Sachar, Chirag, Lucas, Minke, George, Sangeeth, Yan, Patrick K., Kier, Melanie W., Laughlin, Amy I., Kothari, Shawn, Giles, Josephine, Mathew, Divij, Ghinnagow, Reem, Alanio, Cecile, Flowers, Ahron, Xu, Wei, Tenney, Daniel J., Xu, Xiaowei, Amaravadi, Ravi K., Karakousis, Giorgos C., Schuchter, Lynn M., Buggert, Marcus, Oldridge, Derek, Minn, Andy J., Blank, Christian, Weber, Jeffrey S., Mitchell, Tara C., Farwell, Michael D., Herati, Ramin S., and Huang, Alexander C.

Published
2024
Full Text
View/download PDF

2. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity

Author

Zhong, Wenqun, Lu, Youtao, Han, Xuexiang, Yang, Jingbo, Qin, Zhiyuan, Zhang, Wei, Yu, Ziyan, Wu, Bin, Liu, Shujing, Xu, Wei, Zheng, Cathy, Schuchter, Lynn M., Karakousis, Giorgos C., Mitchell, Tara C., Amaravadi, Ravi, Flowers, Ahron J., Gimotty, Phyllis A., Xiao, Min, Mills, Gordon, Herlyn, Meenhard, Dong, Haidong, Mitchell, Michael J., Kim, Junhyong, Xu, Xiaowei, and Guo, Wei

Published
2023
Full Text
View/download PDF

5. Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy

Author

Tcyganov, Evgenii N., Sanseviero, Emilio, Marvel, Douglas, Beer, Thomas, Tang, Hsin-Yao, Hembach, Peter, Speicher, David W., Zhang, Qianfei, Donthireddy, Laxminarasimha R., Mostafa, Ali, Tsyganova, Sabina, Pisarev, Vladimir, Laufer, Terri, Ignatov, Dmitriy, Ferrone, Soldano, Meyer, Christiane, Maby-El Hajjami, Hélène, Speiser, Daniel E., Altiok, Sooner, Antonia, Scott, Xu, Xiaowei, Xu, Wei, Zheng, Cathy, Schuchter, Lynn M., Amaravadi, Ravi K., Mitchell, Tara C., Karakousis, Giorgos C., Yuan, Zhe, Montaner, Luis J., Celis, Esteban, and Gabrilovich, Dmitry I.

Published
2022
Full Text
View/download PDF

6. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

Author

Herati, Ramin Sedaghat, Knorr, David A., Vella, Laura A., Silva, Luisa Victoria, Chilukuri, Lakshmi, Apostolidis, Sokratis A., Huang, Alexander C., Muselman, Alexander, Manne, Sasikanth, Kuthuru, Oliva, Staupe, Ryan P., Adamski, Sharon A., Kannan, Senthil, Kurupati, Raj K., Ertl, Hildegund C. J., Wong, Jeffrey L., Bournazos, Stylianos, McGettigan, Suzanne, Schuchter, Lynn M., Kotecha, Ritesh R., Funt, Samuel A., Voss, Martin H., Motzer, Robert J., Lee, Chung-Han, Bajorin, Dean F., Mitchell, Tara C., Ravetch, Jeffrey V., and Wherry, E. John

Published
2022
Full Text
View/download PDF

7. Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers

Author

Giles, Josephine R., Manne, Sasikanth, Freilich, Elizabeth, Oldridge, Derek A., Baxter, Amy E., George, Sangeeth, Chen, Zeyu, Huang, Hua, Chilukuri, Lakshmi, Carberry, Mary, Giles, Lydia, Weng, Nan-Ping P., Young, Regina M., June, Carl H., Schuchter, Lynn M., Amaravadi, Ravi K., Xu, Xiaowei, Karakousis, Giorgos C., Mitchell, Tara C., Huang, Alexander C., Shi, Junwei, and Wherry, E. John

Published
2022
Full Text
View/download PDF

9. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Author

Long, Georgina, Eroglu, Zeynep, Infante, Jeffrey, Patel, Sapna, Johnson, Douglas, Gonzalez, Rene, Kefford, Richard, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Sharfman, William, McWilliams, Robert, Sznol, Mario, Redhu, Suman, Gasal, Eduard, Mookerjee, Bijoyesh, Weber, Jeffrey, Flaherty, Keith, and Daud, Adil

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Imidazoles, Male, Melanoma, Middle Aged, Mutation, Oximes, Proto-Oncogene Proteins B-raf, Pyridones, Pyrimidinones, Young Adult
Abstract

Purpose To report 5-year landmark analysis efficacy and safety outcomes in patients with BRAF V600-mutant metastatic melanoma (MM) who received BRAF inhibitor dabrafenib (D) and MEK inhibitor trametinib (T) combination therapy versus D monotherapy in the randomized phase II BRF113220 study part C. Patients and Methods BRAF inhibitor-naive patients with BRAF V600-mutant MM were randomly assigned 1:1:1 to receive D 150 mg twice a day, D 150 mg twice a day plus T 1 mg once daily, or D 150 mg twice a day plus T 2 mg once daily (D + T 150/2). Patients who received D monotherapy could cross over to D + T 150/2 postprogression. Efficacy and safety were analyzed 4 and 5 years after initiation in patients with ≥ 5 years of follow-up. Results As of October 13, 2016, 18 patients who received D + T 150/2 remained in the study (13 [24%] of 54 enrolled at this dose plus five [11%] of 45 initially administered D who crossed over to D + T). With D + T 150/2, overall survival (OS; 4 years, 30%; 5 years, 28%) and progression-free survival (4 and 5 years, both 13%) appeared to stabilize with extended follow-up. Increased OS was observed in patients who received D + T with baseline normal lactate dehydrogenase (5 years, 45%) and normal lactate dehydrogenase with fewer than three organ sites with metastasis (5 years, 51%). With extended follow-up, one additional patient who received D + T 150/2 improved from a partial to a complete response. No new safety signals were observed. Conclusion This 5-year analysis represents the longest follow-up to date with BRAF + MEK inhibitor combination therapy in BRAF V600-mutant MM. Consistent with trends observed in landmark analyses with shorter follow-up, this therapy elicits durable plateaus of long-term OS and progression-free survival that last ≥ 5 years in some patients with MM.

Published
2018

11. HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors

Author

Guan, Lei, Wu, Bin, Li, Ting, Beer, Lynn A., Sharma, Gaurav, Li, Mingyue, Lee, Chin Nien, Liu, Shujing, Yang, Changsong, Huang, Lili, Frederick, Dennie T., Boland, Genevieve M., Shao, Guangcan, Svitkina, Tatyana M., Cai, Kathy Q., Chen, Fangping, Dong, Meng-Qiu, Mills, Gordon B., Schuchter, Lynn M., Karakousis, Giorgos C., Mitchell, Tara C., Flaherty, Keith T., Speicher, David W., Chen, Youhai H., Herlyn, Meenhard, Amaravadi, Ravi K., Xu, Xiaowei, and Guo, Wei

Published
2022
Full Text
View/download PDF

13. Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer

Author

Kwak, Taekyoung, Wang, Fang, Deng, Hui, Condamine, Thomas, Kumar, Vinit, Perego, Michela, Kossenkov, Andrew, Montaner, Luis J., Xu, Xiaowei, Xu, Wei, Zheng, Cathy, Schuchter, Lynn M., Amaravadi, Ravi K., Mitchell, Tara C., Karakousis, Giorgos C., Mulligan, Charles, Nam, Brian, Masters, Gregory, Hockstein, Neil, Bennett, Joseph, Nefedova, Yulia, and Gabrilovich, Dmitry I.

Published
2020
Full Text
View/download PDF

14. Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

Author

Beltra, Jean-Christophe, Manne, Sasikanth, Abdel-Hakeem, Mohamed S., Kurachi, Makoto, Giles, Josephine R., Chen, Zeyu, Casella, Valentina, Ngiow, Shin Foong, Khan, Omar, Huang, Yinghui Jane, Yan, Patrick, Nzingha, Kito, Xu, Wei, Amaravadi, Ravi K., Xu, Xiaowei, Karakousis, Giorgos C., Mitchell, Tara C., Schuchter, Lynn M., Huang, Alexander C., and Wherry, E. John

Published
2020
Full Text
View/download PDF

16. Supplementary Table S3 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Yoon, Daniel, primary, Shang, Catherine G., primary, Mick, Rosemarie, primary, Schubert, Erin, primary, McGettigan, Suzanne, primary, Kreider, Kristin, primary, Xu, Wei, primary, Wherry, E. John, primary, Schuchter, Lynn M., primary, Amaravadi, Ravi K., primary, Mitchell, Tara C., primary, and Farwell, Michael D., primary

Published
2024
Full Text
View/download PDF

17. Supplementary Figure S2 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Yoon, Daniel, primary, Shang, Catherine G., primary, Mick, Rosemarie, primary, Schubert, Erin, primary, McGettigan, Suzanne, primary, Kreider, Kristin, primary, Xu, Wei, primary, Wherry, E. John, primary, Schuchter, Lynn M., primary, Amaravadi, Ravi K., primary, Mitchell, Tara C., primary, and Farwell, Michael D., primary

Published
2024
Full Text
View/download PDF

18. Data from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., primary, Huang, Alexander C., primary, Xu, Xiaowei, primary, Yoon, Daniel, primary, Shang, Catherine G., primary, Mick, Rosemarie, primary, Schubert, Erin, primary, McGettigan, Suzanne, primary, Kreider, Kristin, primary, Xu, Wei, primary, Wherry, E. John, primary, Schuchter, Lynn M., primary, Amaravadi, Ravi K., primary, Mitchell, Tara C., primary, and Farwell, Michael D., primary

Published
2024
Full Text
View/download PDF

19. The state of melanoma: challenges and opportunities.

Author

Merlino, Glenn, Herlyn, Meenhard, Fisher, David E, Bastian, Boris C, Flaherty, Keith T, Davies, Michael A, Wargo, Jennifer A, Curiel-Lewandrowski, Clara, Weber, Michael J, Leachman, Sancy A, Soengas, Maria S, McMahon, Martin, Harbour, J William, Swetter, Susan M, Aplin, Andrew E, Atkins, Michael B, Bosenberg, Marcus W, Dummer, Reinhard, Gershenwald, Jeffrey E, Halpern, Allan C, Herlyn, Dorothee, Karakousis, Giorgos C, Kirkwood, John M, Krauthammer, Michael, Lo, Roger S, Long, Georgina V, McArthur, Grant, Ribas, Antoni, Schuchter, Lynn, Sosman, Jeffrey A, Smalley, Keiran S, Steeg, Patricia, Thomas, Nancy E, Tsao, Hensin, Tueting, Thomas, Weeraratna, Ashani, Xu, George, Lomax, Randy, Martin, Alison, Silverstein, Steve, Turnham, Tim, and Ronai, Ze'ev A

Subjects
Humans, Melanoma, Signal Transduction, Biomedical Research, Societies, Scientific, dormancy, early diagnosis, melanoma, metastasis, prevention, therapy, Cancer, Prevention, Vaccine Related, early diagnosis, Biological Sciences, Medical and Health Sciences, Dermatology & Venereal Diseases
Abstract

The Melanoma Research Foundation (MRF) has charted a comprehensive assessment of the current state of melanoma research and care. Intensive discussions among members of the MRF Scientific Advisory Council and Breakthrough Consortium, a group that included clinicians and scientists, focused on four thematic areas - diagnosis/early detection, prevention, tumor cell dormancy (including metastasis), and therapy (response and resistance). These discussions extended over the course of 2015 and culminated at the Society of Melanoma Research 2015 International Congress in November. Each of the four groups has outlined their thoughts as per the current status, challenges, and opportunities in the four respective areas. The current state and immediate and long-term needs of the melanoma field, from basic research to clinical management, are presented in the following report.

Published
2016

20. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma

Author

Webster, Marie R., Fane, Mitchell E., Alicea, Gretchen M., Basu, Subhasree, Kossenkov, Andrew V., Marino, Gloria E., Douglass, Stephen M., Kaur, Amanpreet, Ecker, Brett L., Gnanapradeepan, Keerthana, Ndoye, Abibatou, Kugel, Curtis, Valiga, Alexander, Palmer, Jessica, Liu, Qin, Xu, Xiaowei, Morris, Jessicamarie, Yin, Xiangfan, Wu, Hong, Xu, Wei, Zheng, Cathy, Karakousis, Giorgos C., Amaravadi, Ravi K., Mitchell, Tara C., Almeida, Filipe V., Xiao, Min, Rebecca, Vito W., Wang, Ying-Jie, Schuchter, Lynn M., Herlyn, Meenhard, Murphy, Maureen E., and Weeraratna, Ashani T.

Published
2020
Full Text
View/download PDF

22. Behavioral economic implementation strategies to improve serious illness communication between clinicians and high-risk patients with cancer: protocol for a cluster randomized pragmatic trial

Author

Takvorian, Samuel U., Bekelman, Justin, Beidas, Rinad S., Schnoll, Robert, Clifton, Alicia B. W., Salam, Tasnim, Gabriel, Peter, Wileyto, E. Paul, Scott, Callie A., Asch, David A., Buttenheim, Alison M., Rendle, Katharine A., Chaiyachati, Krisda, Shelton, Rachel C., Ware, Sue, Chivers, Corey, Schuchter, Lynn M., Kumar, Pallavi, Shulman, Lawrence N., O’Connor, Nina, Lieberman, Adina, Zentgraf, Kelly, and Parikh, Ravi B.

Published
2021
Full Text
View/download PDF

23. FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Author

Anderson, Thomas M., primary, Chang, Bryan H., additional, Huang, Alexander C., additional, Xu, Xiaowei, additional, Yoon, Daniel, additional, Shang, Catherine G., additional, Mick, Rosemarie, additional, Schubert, Erin, additional, McGettigan, Suzanne, additional, Kreider, Kristin, additional, Xu, Wei, additional, Wherry, E. John, additional, Schuchter, Lynn M., additional, Amaravadi, Ravi K., additional, Mitchell, Tara C., additional, and Farwell, Michael D., additional

Published
2024
Full Text
View/download PDF

24. Trial Protocol 1 from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

25. Supplementary Data 1 from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

26. Data from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

27. Supplementary Figure 1 from A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, primary, Shaheen, Montaser, primary, Berciano-Guerrero, Miguel-Ángel, primary, Couselo, Eva Muñoz, primary, Rodríguez-Abreu, Delvys, primary, Boni, Valentina, primary, Schuchter, Lynn M., primary, Gonzalez-Cao, Maria, primary, Arance, Ana, primary, Wei, Wei, primary, Ganti, Apar Kishor, primary, Hauke, Ralph J., primary, Berrocal, Alfonso, primary, Iannotti, Nicholas O., primary, Hsu, Frank J., primary, and Kluger, Harriet M., primary

Published
2024
Full Text
View/download PDF

28. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

Author

Johnson, Douglas B, Flaherty, Keith T, Weber, Jeffrey S, Infante, Jeffrey R, Kim, Kevin B, Kefford, Richard F, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Sharfman, William H, McWilliams, Robert R, Sznol, Mario, Lawrence, Donald P, Gibney, Geoffrey T, Burris, Howard A, Falchook, Gerald S, Algazi, Alain, Lewis, Karl, Long, Georgina V, Patel, Kiran, Ibrahim, Nageatte, Sun, Peng, Little, Shonda, Cunningham, Elizabeth, Sosman, Jeffrey A, Daud, Adil, and Gonzalez, Rene

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Cancer, Development of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Disease-Free Survival, Female, Humans, Imidazoles, Male, Melanoma, Middle Aged, Mitogen-Activated Protein Kinase Kinases, Mutation, Oximes, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Pyridones, Pyrimidinones, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePreclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had received prior BRAF inhibitor treatment.Patients and methodsIn this open-label phase I/II study, we evaluated the pharmacology, safety, and efficacy of dabrafenib and trametinib. Here, we report patients treated with combination therapy after disease progression with BRAF inhibitor treatment administered before study enrollment (part B; n = 26) or after cross-over at progression with dabrafenib monotherapy (part C; n = 45).ResultsIn parts B and C, confirmed objective response rates (ORR) were 15% (95% CI, 4% to 35%) and 13% (95% CI, 5% to 27%), respectively; an additional 50% and 44% experienced stable disease ≥ 8 weeks, respectively. In part C, median progression-free survival (PFS) was 3.6 months (95% CI, 2 to 4), and median overall survival was 11.8 months (95% CI, 8 to 25) from cross-over. Patients who previously received dabrafenib ≥ 6 months had superior outcomes with the combination compared with those treated < 6 months; median PFS was 3.9 (95% CI, 3 to 7) versus 1.8 months (95% CI, 2 to 4; hazard ratio, 0.49; P = .02), and ORR was 26% (95% CI, 10% to 48%) versus 0% (95% CI, 0% to 15%).ConclusionDabrafenib plus trametinib has modest clinical efficacy in patients with BRAF inhibitor-resistant melanoma. This regimen may be a therapeutic strategy for patients who previously benefited from BRAF inhibitor monotherapy ≥ 6 months but demonstrates minimal efficacy after rapid progression with BRAF inhibitor therapy.

Published
2014

29. SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy

Author

Sun, Lova, Surya, Sanjna, Goodman, Noah G., Le, Anh N., Kelly, Gregory, Owoyemi, Olutosin, Desai, Heena, Zheng, Cathy, DeLuca, Shannon, Good, Madeline L., Hussain, Jasmin, Jeffries, Seth D., Kry, Yolanda R., Kugler, Emily M., Mansour, Maikel, Ndicu, John, Osei-Akoto, AnnaClaire, Prior, Timothy, Pundock, Stacy L., Varughese, Lisa A., Weaver, JoEllen, Doucette, Abigail, Dudek, Scott, Verma, Shefali Setia, Gouma, Sigrid, Weirick, Madison E., McAllister, Christopher M., Bange, Erin, Gabriel, Peter, Ritchie, Marylyn, Rader, Daniel J., Vonderheide, Robert H., Schuchter, Lynn M., Verma, Anurag, Maillard, Ivan, Mamtani, Ronac, Hensley, Scott E., Gross, Robert, Wileyto, E. Paul, Huang, Alexander C., Maxwell, Kara N., and DeMichele, Angela

Published
2021
Full Text
View/download PDF

30. A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

Author

Flaherty, Lawrence, Hamid, Omid, Linette, Gerald, Schuchter, Lynn, Hallmeyer, Sigrun, Gonzalez, Rene, Cowey, C Lance, Pavlick, Anna, Kudrik, Fred, Curti, Brendan, Lawson, David, Chapman, Paul B, Margolin, Kim, Ribas, Antoni, McDermott, David, Flaherty, Keith, Cranmer, Lee, Hodi, F Stephen, Day, Bann-Mo, Linke, Rolf, and Hainsworth, John

Subjects
Cancer, Clinical Trials and Supportive Activities, Patient Safety, Neurosciences, Clinical Research, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Skin Neoplasms, Sulfonamides, United States, Vemurafenib, Melanoma/drug therapy, melanoma/genetics, BRAF protein, human, neoplasm metastasis/drug therapy, brain neoplasms/secondary, brain neoplasms/drug therapy, vemurafenib/therapeutic use, vemurafenib/adverse effects, clinical trial, humans, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThis open-label, multicenter study was designed to allow access to vemurafenib for patients with metastatic melanoma, bridging the time between end of enrollment in the phase III registration trial (December 2010) and commercial availability following US Food and Drug Administration approval of vemurafenib for the treatment of unresectable or metastatic BRAF-mutated melanoma (August 2011).Patients and methodsEligible patients had metastatic melanoma with a BRAF mutation (detected by the cobas 4800 BRAF V600 Mutation Test). Unlike previous vemurafenib trials, patients with poor performance status (PS) and treated brain metastases were permitted. Enrolled patients received oral vemurafenib 960 mg twice daily.ResultsOf 374 patients enrolled at 29 US sites (December 2010 to October 2011), 371 patients received vemurafenib and were followed up for a median of 2.8 months (the study had a prespecified end upon vemurafenib approval and commercial availability). At baseline, most patients (75%) had stage M1c disease, and 19% had an Eastern Cooperative Oncology Group PS of 2 or 3; 72% of patients had received prior systemic therapy for metastatic melanoma, 27% received prior ipilimumab, and 29% radiotherapy for prior brain metastases. Because reassessment data to confirm response were not available for most patients, point estimates of objective response rate (ORR) are reported. Among 241 efficacy-evaluable patients, the ORR was 54% (median time to response, 1.9 months). The ORR in non-central nervous system sites in patients with previously treated brain metastases (n = 68) was 53%. The ORR in prior ipilimumab-treated patients (n = 68) was 52%. For patients with PS of 0 or 1 (n = 210) and 2 or 3 (n = 31), the ORRs were 55%, and 42%, respectively. The safety profile observed was consistent with that reported in previous studies. The number of patients with grade 3 or 4 treatment-related adverse events was higher in patients with PS 2 or 3 than in those with PS 0 or 1 (10% vs. 5%, respectively). Adverse events requiring a dose reduction (at least 1 level) occurred in 11% of patients, and 9 patients (2%) experienced events leading to vemurafenib withdrawal, including 2 with repeated QT interval prolongation.DiscussionThis study confirmed the established rapid and high tumor response rate achievable with vemurafenib in BRAF mutation-positive metastatic melanoma. Several groups not included in previous studies, including patients with previously treated brain metastases, Eastern Cooperative Oncology Group PS 2 to 3, or previous ipilimumab treatment had benefitted from vemurafenib similar to the overall population. No new safety signals were detected.

Published
2014

32. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

Author

Khan, Omar, Giles, Josephine R., McDonald, Sierra, Manne, Sasikanth, Ngiow, Shin Foong, Patel, Kunal P., Werner, Michael T., Huang, Alexander C., Alexander, Katherine A., Wu, Jennifer E., Attanasio, John, Yan, Patrick, George, Sangeeth M., Bengsch, Bertram, Staupe, Ryan P., Donahue, Greg, Xu, Wei, Amaravadi, Ravi K., Xu, Xiaowei, Karakousis, Giorgos C., Mitchell, Tara C., Schuchter, Lynn M., Kaye, Jonathan, Berger, Shelley L., and Wherry, E. John

Published
2019
Full Text
View/download PDF

33. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Author

Flaherty, Keith T, Infante, Jeffery R, Daud, Adil, Gonzalez, Rene, Kefford, Richard F, Sosman, Jeffrey, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Ibrahim, Nageatte, Kudchadkar, Ragini, Burris, Howard A, Falchook, Gerald, Algazi, Alain, Lewis, Karl, Long, Georgina V, Puzanov, Igor, Lebowitz, Peter, Singh, Ajay, Little, Shonda, Sun, Peng, Allred, Alicia, Ouellet, Daniele, Kim, Kevin B, Patel, Kiran, and Weber, Jeffrey

Subjects
Clinical Research, Cancer, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Drug Therapy, Combination, Female, Fever, Humans, Imidazoles, MAP Kinase Signaling System, Male, Melanoma, Middle Aged, Mitogen-Activated Protein Kinase Kinases, Mutation, Oximes, Proto-Oncogene Proteins B-raf, Pyridones, Pyrimidinones, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundResistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.MethodsIn this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy. The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response. Secondary end points were overall survival and pharmacokinetic activity.ResultsDose-limiting toxic effects were infrequently observed in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2). Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P=0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%). Median progression-free survival in the combination 150/2 group was 9.4 months, as compared with 5.8 months in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P

Published
2012

34. 579-C Reinvigoration of progenitor-exhausted CD8 T cells by anti-CTLA-4 contributes to the sustained activity of combination checkpoint blockade

Author

Wang, Kevin, primary, Coutifaris, Paulina, additional, Brocks, David, additional, Solis, Sabrina, additional, Han, Nicholas, additional, Manne, Sasikanth, additional, Kiner, Evgeny, additional, Sachar, Chirag, additional, George, Sangeeth, additional, Yan, Patrick, additional, Kiner, Melanie W, additional, Laughlin, Amy I, additional, Kothari, Shawn, additional, Giles, Josephine R, additional, Mathew, Divij, additional, Ghinnagow, Rheem, additional, Alanio, Cecile, additional, Flowers, Ahron, additional, Xu, Wei, additional, Tenney, Daniel, additional, Xu, Xiaowei, additional, Amaravadi, Ravi K, additional, Karakousis, Giorgos C, additional, Schuchter, Lynn M, additional, Buggert, Marcus, additional, John Wherry, E, additional, Minn, Andy, additional, Weber, Jeffrey, additional, Mitchell, Tara, additional, Herati, Ramin S, additional, and Huang, Alexander, additional

Published
2023
Full Text
View/download PDF

35. Remote Patient-Reported Outcomes and Activity Monitoring to Improve Patient-Clinician Communication Regarding Symptoms and Functional Status: A Randomized Controlled Trial

Author

Parikh, Ravi B., primary, Schriver, Emily, additional, Ferrell, William J., additional, Wakim, Jonathan, additional, Williamson, Joelle, additional, Khan, Neda, additional, Kopinsky, Michael, additional, Balachandran, Mohan, additional, Gabriel, Peter E., additional, Schuchter, Lynn M., additional, Patel, Mitesh S., additional, Shulman, Lawrence N., additional, and Manz, Christopher R., additional

Published
2023
Full Text
View/download PDF

37. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines

Author

Garman, Bradley, Anastopoulos, Ioannis N., Krepler, Clemens, Brafford, Patricia, Sproesser, Katrin, Jiang, Yuchao, Wubbenhorst, Bradley, Amaravadi, Ravi, Bennett, Joseph, Beqiri, Marilda, Elder, David, Flaherty, Keith T., Frederick, Dennie T., Gangadhar, Tara C., Guarino, Michael, Hoon, David, Karakousis, Giorgos, Liu, Qin, Mitra, Nandita, Petrelli, Nicholas J., Schuchter, Lynn, Shannan, Batool, Shields, Carol L., Wargo, Jennifer, Wenz, Brandon, Wilson, Melissa A., Xiao, Min, Xu, Wei, Xu, Xaiowei, Yin, Xiangfan, Zhang, Nancy R., Davies, Michael A., Herlyn, Meenhard, and Nathanson, Katherine L.

Published
2017
Full Text
View/download PDF

38. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

Author

Krepler, Clemens, Sproesser, Katrin, Brafford, Patricia, Beqiri, Marilda, Garman, Bradley, Xiao, Min, Shannan, Batool, Watters, Andrea, Perego, Michela, Zhang, Gao, Vultur, Adina, Yin, Xiangfan, Liu, Qin, Anastopoulos, Ioannis N., Wubbenhorst, Bradley, Wilson, Melissa A., Xu, Wei, Karakousis, Giorgos, Feldman, Michael, Xu, Xiaowei, Amaravadi, Ravi, Gangadhar, Tara C., Elder, David E., Haydu, Lauren E., Wargo, Jennifer A., Davies, Michael A., Lu, Yiling, Mills, Gordon B., Frederick, Dennie T., Barzily-Rokni, Michal, Flaherty, Keith T., Hoon, Dave S., Guarino, Michael, Bennett, Joseph J., Ryan, Randall W., Petrelli, Nicholas J., Shields, Carol L., Terai, Mizue, Sato, Takami, Aplin, Andrew E., Roesch, Alexander, Darr, David, Angus, Steve, Kumar, Rakesh, Halilovic, Ensar, Caponigro, Giordano, Jeay, Sebastien, Wuerthner, Jens, Walter, Annette, Ocker, Matthias, Boxer, Matthew B., Schuchter, Lynn, Nathanson, Katherine L., and Herlyn, Meenhard

Published
2017
Full Text
View/download PDF

39. Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy

Author

Zhang, Ying, Kurupati, Raj, Liu, Ling, Zhou, Xiang Yang, Zhang, Gao, Hudaihed, Abeer, Filisio, Flavia, Giles-Davis, Wynetta, Xu, Xiaowei, Karakousis, Giorgos C., Schuchter, Lynn M., Xu, Wei, Amaravadi, Ravi, Xiao, Min, Sadek, Norah, Krepler, Clemens, Herlyn, Meenhard, Freeman, Gordon J., Rabinowitz, Joshua D., and Ertl, Hildegund C.J.

Published
2017
Full Text
View/download PDF

40. Contributors

Author

Abbruzzese, James L., primary, Abdel-Wahab, Omar, additional, Abou-Alfa, Ghassan K., additional, Abrahm, Janet L., additional, Abrams, Jeffrey S., additional, Abramson, Jeremy S., additional, Aisner, Dara L., additional, Alonso-Basanta, Michelle, additional, Anampa, Jesus, additional, Anderson, Megan E., additional, Antonarakis, Emmanuel S., additional, Aplenc, Richard, additional, Appelbaum, Frederick R., additional, Araujo, Luiz H., additional, Asban, Ammar, additional, Ashwood, Edward, additional, Awan, Farrukh T., additional, Aylward, Juliet L., additional, Balar, Arjun V., additional, Balentine, Courtney J., additional, Barta, Stefan K., additional, Bartlett, Nancy, additional, Basen-Engquist, Karen, additional, Beaupin, Lynda Kwon, additional, Berkowitz, Ross S., additional, Berry, Donald A., additional, Bevers, Therese, additional, Boggess, John F., additional, Brahmer, Julie R., additional, Brown, Janet, additional, Brown, Karen, additional, Brown, Powel, additional, Browner, Ilene, additional, Bunn, Paul A., additional, Burns, William R., additional, Byrd, John C., additional, Cadoo, Karen, additional, Carbone, David P., additional, Carter, H. Ballentine, additional, Castillo, Jorge J., additional, Chang, Alfred E., additional, Chang, Eric, additional, Chanock, Stephen J., additional, Chapuy, Claudia I., additional, Chauhan, Vikash P., additional, Chen, Herbert, additional, Chen, Ronald C., additional, Cheung, Nai-Kong V., additional, Choe, Jennifer H., additional, Christian, Michaele C., additional, Cinciripini, Paul M., additional, Clarke, Michael F., additional, Coleman, Robert E., additional, Coleman, Robert L., additional, Coletta, Adriana M., additional, Collins, Jerry M., additional, Connors, Jean M., additional, Cools, Michael, additional, Coombes, Kevin R., additional, Cortes, Jorge, additional, Costa, Mauro W., additional, Covey, Anne, additional, Cowan, Kenneth H., additional, Crane, Christopher H., additional, Crawford, Jeffrey, additional, Crooks, Kristy, additional, Culkin, Daniel J., additional, Czito, Brian G., additional, Dalerba, Piero, additional, Dalmau, Josep, additional, Dang, Mai, additional, D'Angelica, Michael, additional, Davies, Kurtis D., additional, Davis, Myrtle, additional, Dea, Nicolas, additional, De Jesus-Acosta, Ana, additional, DeMarzo, Angelo M., additional, DeWeese, Theodore L., additional, Diehn, Maximilian, additional, Digumarthy, Subba R., additional, Dispenzieri, Angela, additional, Do, Khanh T., additional, Dobrenkov, Konstantin, additional, Dome, Jeffrey S., additional, Doroshow, James H., additional, Dorsey, Jay F., additional, Dubard-Gault, Marianne, additional, DuBois, Steven G., additional, Duda, Dan G., additional, Dunlop, Malcolm, additional, Duska, Linda R., additional, Duvic, Madeleine, additional, El Dika, Imane, additional, El-Serag, Hashem, additional, Engelmann, Jeffrey M., additional, Ettinger, David S., additional, Fashoyin-Aje, Lola A., additional, Fearon, Eric R., additional, Ford, James M., additional, Franklin, Wilbur A., additional, Freer, Phoebe E., additional, Freidlin, Boris, additional, Freifeld, Alison G., additional, Friedlander, Terence W., additional, Friedman, Debra L., additional, Fuller, Arian F., additional, Galluzzi, Lorenzo, additional, Gebhardt, Mark C., additional, George, Daniel J., additional, Geyer, Mark B., additional, Giaccia, Amato J., additional, Gilbert, Mark R., additional, Goldner, Whitney, additional, Goldstein, Donald P., additional, Goodman, Annekathryn, additional, Goodman, Karyn A., additional, Gordon, Kathleen, additional, Graeff-Armas, Laura, additional, Greenstein, Alexander J., additional, Grossman, Stuart A., additional, Grupp, Stephan, additional, Gupta, Arjun, additional, Haider, Irfanullah, additional, Haigentz, Missak, additional, Hainsworth, John D., additional, Haithcock, Benjamin E., additional, Hallemeier, Christopher L., additional, Hanash, Samir, additional, Hanrahan, Aphrothiti J., additional, Harding, James, additional, Harrison, Michael R., additional, Hasham, Muneer G., additional, Hawk, Ernest, additional, Hayman, Jonathan, additional, Heinlen, Jonathan E., additional, Henry, N. Lynn, additional, Herman, Joseph, additional, Hobbs, Brian P., additional, Holen, Ingunn, additional, Horn, Leora, additional, Horowitz, Neil S., additional, Horwitz, Steven M., additional, Houghton, Odette, additional, Howard, Scott C., additional, Hudis, Clifford A., additional, Hunger, Stephen P., additional, Hurria, Arti, additional, Ilson, David H., additional, Im, Annie, additional, Iyer, Gopa, additional, Jaffee, Elizabeth M., additional, Jagsi, Reshma, additional, Jain, Rakesh K., additional, Jarnagin, William, additional, Jatoi, Aminah, additional, Jhingran, Anuja, additional, Johnson, David H., additional, Johnston, Brian, additional, Johnston, Patrick G., additional, Judy, Kevin D., additional, Kachnic, Lisa A., additional, Kaidar-Person, Orit, additional, Kalva, Sanjeeva, additional, Kamin, Deborah Y., additional, Kantarjian, Hagop, additional, Karakousis, Giorgos, additional, Karam-Hage, Maher, additional, Kaskas, Nadine M., additional, Kastan, Michael B., additional, Katabi, Nora, additional, Kaul, Daniel R., additional, Kelley, Scott R., additional, Kemeny, Nancy, additional, Kent, Erin E., additional, Kepp, Oliver, additional, Khagi, Simon, additional, Kilgore, Joshua E., additional, Kim, D. Nathan, additional, Kleinschmidt-DeMasters, Bette K., additional, Korn, Edward L., additional, Kroemer, Guido, additional, Ku, Geoffrey Y., additional, Kummar, Shivaani, additional, Ky, Bonnie, additional, Laheru, Daniel A., additional, Lambert, Paul F., additional, Lawler, Mark, additional, Le-Rademacher, Jennifer G., additional, Lee, John Y.K., additional, Lee, Nancy Y., additional, Lee, Susanna L., additional, Leeman, Jonathan E., additional, Linkermann, Andreas, additional, Liu, Jinsong, additional, Lo, Simon, additional, Locasale, Jason W., additional, Loprinzi, Charles L., additional, Lowery, Maeve, additional, Ludwig, Emmy, additional, Lunning, Matthew A., additional, Lustig, Robert A., additional, Machtay, Mitchell, additional, Mackall, Crystal, additional, Mahvi, David A., additional, Mahvi, David M., additional, Maity, Amit, additional, Majithia, Neil, additional, Malumbres, Marcos, additional, Maresso, Karen Colbert, additional, Martin, John D., additional, Matsuo, Koji, additional, Matthews, Natalie H., additional, Mauro, Lauren, additional, Mayer, R. Samuel, additional, McCaskill-Stevens, Worta, additional, McNamara, Megan A., additional, Mehta-Shah, Neha, additional, Merritt, Robert E., additional, Milowsky, Matthew I., additional, Minasian, Lori M., additional, Mitchell, Tara C., additional, Mitsis, Demytra, additional, Mollica, Michelle, additional, Mooney, Margaret, additional, Moustafa, Farah, additional, Nabati, Lida, additional, Naidoo, Jarushka, additional, Narang, Amol, additional, Nelson, Heidi, additional, Nelson, William G., additional, Nesbit, Suzanne, additional, Niglas, Mark, additional, O'Connor, Tracey, additional, Offit, Kenneth, additional, Onciu, Mihaela, additional, O’Reilly, Eileen M., additional, Ostrander, Elaine A., additional, Pappas-Taffer, Lisa, additional, Pardoll, Drew, additional, Park, Jae H., additional, Patel, Anery, additional, Patel, Anish J., additional, Patierno, Steven R., additional, Pavletic, Steven Z., additional, Phillips, Peter C., additional, Post, Miriam D., additional, Pruitt, Amy A., additional, Querfeld, Christiane, additional, Rabius, Vance A., additional, Rajkumar, S. Vincent, additional, Ramadan, Mohammad O., additional, Rankin, Erinn B., additional, Reddy, Sushanth, additional, Reid, Michael A., additional, Reznik, Scott, additional, Rizack, Tina, additional, Robinson, Jason D., additional, Robinson-Bostom, Leslie, additional, Rodriguez-Galindo, Carlos, additional, Romesser, Paul B., additional, Rosen, Steven T., additional, Rosenfeld, Myrna R., additional, Rosenthal, Nadia, additional, Ross, Meredith, additional, Rowland, Julia H., additional, Russell, Anthony H., additional, Sabel, Michael S., additional, Sahgal, Arjun, additional, Salinas, Ryan D., additional, Salo-Mullen, Erin E., additional, Salto-Tellez, Manuel, additional, Sanderson, Sydney M., additional, Sandlund, John T., additional, Santana, Victor M., additional, Savage, Michelle, additional, Schreiber, Eric C., additional, Schuchter, Lynn, additional, Schultz, Liora, additional, Seiden, Michael V., additional, Sellers, Morgan M., additional, Shah, Payal D., additional, Shia, Jinru, additional, Shilo, Konstantin, additional, Small, Eric, additional, Smith, Angela B., additional, Snow, Stephen N., additional, Solit, David B., additional, Sood, Anil K., additional, Soto-Perez-de-Celis, Enrique, additional, Sparano, Joseph A., additional, Spiegelman, Vladimir S., additional, Spunt, Sheri L., additional, Stadler, Zsofia K., additional, Steensma, David P., additional, Stone, Richard M., additional, Stranne, Steven Kent, additional, Stratton, Kelly, additional, Sugden, Bill, additional, Swanson, Andrew M., additional, Tallman, Martin S., additional, Talmadge, James E., additional, Teachey, David T., additional, Teba, Catalina V., additional, Tefferi, Ayalew, additional, Teh, Bin Tean, additional, Teng, Joyce M.C., additional, Tepper, Joel E., additional, Thaker, Premal H., additional, Thrift, Aaron P., additional, Tran, Arthur-Quan, additional, Triska, Grace, additional, Trump, Donald, additional, Tsai, Kenneth, additional, Tseng, Chia-Lin, additional, Tseng, Diane, additional, Van Schaeybroeck, Sandra, additional, Van Tine, Brian A., additional, Vanness, Erin R., additional, Varadhachary, Gauri, additional, Varella-Garcia, Marileila, additional, Wahl, Richard L., additional, Walsh, Michael F., additional, Wang, Thomas, additional, Weiss, Jared, additional, Weissman, Irving L., additional, Westin, Shannon N., additional, White, Jeffrey D., additional, Wilson, Richard, additional, Wong, Richard J., additional, Wood, Gary S., additional, Xu, Yaohui G., additional, Xu-Welliver, Meng, additional, Yust-Katz, Shlomit, additional, Zagar, Timothy, additional, Zeman, Elaine M., additional, Zhang, Tian, additional, and Zwiebel, James A., additional

Published
2020
Full Text
View/download PDF

41. Melanoma

Author

Mitchell, Tara C., primary, Karakousis, Giorgos, additional, and Schuchter, Lynn, additional

Published
2020
Full Text
View/download PDF

44. Chemotherapy for Melanoma

Author

Wilson, Melissa A., Schuchter, Lynn M., Rosen, Steven T., Series editor, Kaufman, Howard L., editor, and Mehnert, Janice M., editor

Published
2016
Full Text
View/download PDF

45. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours

Author

Maity, Amit, Mick, Rosemarie, Huang, Alexander C., George, Sangeeth M., Farwell, Michael D., Lukens, John N., Berman, Abigail T., Mitchell, Tara C., Bauml, Josh, Schuchter, Lynn M., O’Hara, Mark, Lin, Lilie L., Demichele, Angela, Christodouleas, John P., Haas, Naomi B., Patsch, Dana M., Hahn, Stephen M., Minn, Andy J., Wherry, E. John, and Vonderheide, Robert H.

Published
2018
Full Text
View/download PDF

46. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Author

Chen, Gang, Huang, Alexander C., Zhang, Wei, Zhang, Gao, Wu, Min, Xu, Wei, Yu, Zili, Yang, Jiegang, Wang, Beike, Sun, Honghong, Xia, Houfu, Man, Qiwen, Zhong, Wenqun, Antelo, Leonardo F., Wu, Bin, Xiong, Xuepeng, Liu, Xiaoming, Guan, Lei, Li, Ting, Liu, Shujing, Yang, Ruifeng, Lu, Youtao, Dong, Liyun, McGettigan, Suzanne, Somasundaram, Rajasekharan, Radhakrishnan, Ravi, Mills, Gordon, Lu, Yiling, Kim, Junhyong, Chen, Youhai H., Dong, Haidong, Zhao, Yifang, Karakousis, Giorgos C., Mitchell, Tara C., Schuchter, Lynn M., Herlyn, Meenhard, Wherry, E. John, Xu, Xiaowei, and Guo, Wei

Published
2018
Full Text
View/download PDF

47. A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Author

Weiss, Sarah A., primary, Sznol, Mario, additional, Shaheen, Montaser, additional, Berciano-Guerrero, Miguel-Ángel, additional, Couselo, Eva Muñoz, additional, Rodríguez-Abreu, Delvys, additional, Boni, Valentina, additional, Schuchter, Lynn M., additional, Gonzalez-Cao, Maria, additional, Arance, Ana, additional, Wei, Wei, additional, Ganti, Apar Kishor, additional, Hauke, Ralph J., additional, Berrocal, Alfonso, additional, Iannotti, Nicholas O., additional, Hsu, Frank J., additional, and Kluger, Harriet M., additional

Published
2023
Full Text
View/download PDF

50. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

Author

Weber, Jeffrey S, Gibney, Geoff, Sullivan, Ryan J, Sosman, Jeffrey A, Slingluff, Craig L, Jr, Lawrence, Donald P, Logan, Theodore F, Schuchter, Lynn M, Nair, Suresh, Fecher, Leslie, Buchbinder, Elizabeth I, Berghorn, Elmer, Ruisi, Mary, Kong, George, Jiang, Joel, Horak, Christine, and Hodi, F Stephen

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results